BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

...Management LLLP acquired an exclusive license to a topical synthetic analog of RvE1, RX-10045, from Resolvyx Pharmaceuticals Inc....
...1, 2010) . Michael Leviten Auven Therapeutics Management LLLP Beth Israel Deaconess Medical Center Brigham and Women's Hospital Harvard Medical School Resolvyx Pharmaceuticals Inc. Resolvin...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...Corp. She also had held R&D positions at Boston area companies Concert Pharmaceuticals Inc. and Resolvyx Pharmaceuticals Inc....
...Ltd., Shanghai, China Pfizer Inc. (NYSE:PFE), New York, N.Y. Qilu Pharmaceutical Co. Ltd., Jinan, China Resolvyx Pharmaceuticals Inc....
BioCentury | Jul 15, 2013
Company News

Warp Drive Bio management update

...Genomics Hired: James Nichols as COO, a newly created position, formerly president and COO of Resolvyx Pharmaceuticals Inc....
BioCentury | Jul 3, 2013
Company News

Warp Drive names Verdine CEO

...hired James Nichols as COO, a newly created position. Nichols was president and COO of Resolvyx Pharmaceuticals Inc....
BioCentury | May 31, 2012
Distillery Therapeutics

Indication: Infectious disease

...Next steps could include testing RvD1 and RvD5 in other mouse models of bacterial infection. Resolvyx Pharmaceuticals Inc....
BioCentury | Jan 17, 2011
Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

...2010 option from Resolvyx to receive exclusive, worldwide rights to RX-10045 for all ophthalmic indications. Resolvyx...
...fund all further development costs of the topical synthetic analog of resolvin E1 (RvE1) . Resolvyx...
...half. Celtic may also license rights to develop a topical formulation of a second undisclosed Resolvyx...
BioCentury | Nov 1, 2010
Finance

Celtic's Big Top Off

...to run late-stage clinical trials." Last week, Celtic announced it received an exclusive option from Resolvyx Pharmaceuticals Inc....
...smaller, critical care indications. As part of the deal, Celtic purchased a convertible note from Resolvyx...
BioCentury | Nov 1, 2010
Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

...for ophthalmic indications. As part of the option agreement, Celtic purchased a convertible note from Resolvyx...
...Further details were not disclosed. Celtic Therapeutics Holdings L.P. , St. Thomas, U.S. Virgin Islands Resolvyx Pharmaceuticals Inc....
BioCentury | Oct 27, 2010
Company News

Resolvyx grants Celtic RX-10045 option

...for ophthalmic indications. As part of the option agreement, Celtic purchased a convertible note from Resolvyx...
BioCentury | Oct 18, 2010
Company News

Shire management update

...Philip Vickers as SVP of R&D for human genetic therapies, formerly president and CSO of Resolvyx Pharmaceuticals Inc. WIR...
Items per page:
1 - 10 of 38
BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

...Management LLLP acquired an exclusive license to a topical synthetic analog of RvE1, RX-10045, from Resolvyx Pharmaceuticals Inc....
...1, 2010) . Michael Leviten Auven Therapeutics Management LLLP Beth Israel Deaconess Medical Center Brigham and Women's Hospital Harvard Medical School Resolvyx Pharmaceuticals Inc. Resolvin...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...Corp. She also had held R&D positions at Boston area companies Concert Pharmaceuticals Inc. and Resolvyx Pharmaceuticals Inc....
...Ltd., Shanghai, China Pfizer Inc. (NYSE:PFE), New York, N.Y. Qilu Pharmaceutical Co. Ltd., Jinan, China Resolvyx Pharmaceuticals Inc....
BioCentury | Jul 15, 2013
Company News

Warp Drive Bio management update

...Genomics Hired: James Nichols as COO, a newly created position, formerly president and COO of Resolvyx Pharmaceuticals Inc....
BioCentury | Jul 3, 2013
Company News

Warp Drive names Verdine CEO

...hired James Nichols as COO, a newly created position. Nichols was president and COO of Resolvyx Pharmaceuticals Inc....
BioCentury | May 31, 2012
Distillery Therapeutics

Indication: Infectious disease

...Next steps could include testing RvD1 and RvD5 in other mouse models of bacterial infection. Resolvyx Pharmaceuticals Inc....
BioCentury | Jan 17, 2011
Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

...2010 option from Resolvyx to receive exclusive, worldwide rights to RX-10045 for all ophthalmic indications. Resolvyx...
...fund all further development costs of the topical synthetic analog of resolvin E1 (RvE1) . Resolvyx...
...half. Celtic may also license rights to develop a topical formulation of a second undisclosed Resolvyx...
BioCentury | Nov 1, 2010
Finance

Celtic's Big Top Off

...to run late-stage clinical trials." Last week, Celtic announced it received an exclusive option from Resolvyx Pharmaceuticals Inc....
...smaller, critical care indications. As part of the deal, Celtic purchased a convertible note from Resolvyx...
BioCentury | Nov 1, 2010
Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

...for ophthalmic indications. As part of the option agreement, Celtic purchased a convertible note from Resolvyx...
...Further details were not disclosed. Celtic Therapeutics Holdings L.P. , St. Thomas, U.S. Virgin Islands Resolvyx Pharmaceuticals Inc....
BioCentury | Oct 27, 2010
Company News

Resolvyx grants Celtic RX-10045 option

...for ophthalmic indications. As part of the option agreement, Celtic purchased a convertible note from Resolvyx...
BioCentury | Oct 18, 2010
Company News

Shire management update

...Philip Vickers as SVP of R&D for human genetic therapies, formerly president and CSO of Resolvyx Pharmaceuticals Inc. WIR...
Items per page:
1 - 10 of 38